Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 8, 2010
Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatmentHiginio Dopeso, Silvia Mateo-Lozano, Elena Elez, et al.
Cancer Research|April 24, 2014
Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancerDmitri Mouradov, Clare Sloggett, Robert N Jorissen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2017
ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor TypesAnderly C Chüeh, Janson W T Tse, Michael Dickinson, et al.
Cell Death Discovery|December 10, 2020
BCL-XL is an actionable target for treatment of malignant pleural mesotheliomaSurein Arulananda, Megan O'Brien, Marco Evangelista, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2012
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agentsMuling Mao, Feng Tian, John M Mariadason, et al.
Cell Death & Disease|April 26, 2019
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survivalErinna F Lee, Tiffany J Harris, Sharon Tran, et al.
BMJ Oncology|October 29, 2025
Sensory neuropeptide CGRP and its co-receptor RAMP1 drive tumour cell growth in gastrointestinal cancersPavitha Parathan, Kelly Tran, Liam Neil, et al.
Proteomics|April 30, 2015
FunRich: An open access standalone functional enrichment and interaction network analysis toolMohashin Pathan, Shivakumar Keerthikumar, Ching-Seng Ang, et al.
Cell Death & Disease|March 1, 2024
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAFV600E colorectal cancerLaura J Jenkins, Ian Y Luk, Fiona Chionh, et al.
Pageof 12